{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:22:31Z","timestamp":1756902151289,"version":"3.44.0"},"reference-count":19,"publisher":"The Pediatric Pharmacy Association","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>Inhaled nitric oxide (iNO) is a mainstay of treatment for infants with persistent pulmonary \u00adhypertension. However, abrupt discontinuation of inhaled nitric oxide can result in rebound pulmonary \u00adhypertension. The objective of this analysis is to describe the use of sildenafil to facilitate the weaning from iNO in preterm neonates.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>This retrospective chart review identified all infants who were receiving iNO and subsequently received sildenafil between 2017 and 2021. Neonates were included if they met the following criteria: gestational age at birth less than 34 weeks, receiving iNO, and started on sildenafil with the indication to facilitate weaning or discontinuation of iNO. Patients were excluded if they had major congenital anomalies, including congenital heart disease or congenital diaphragmatic hernia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>We identified 7 neonates with a gestational age range of 22 5\/7 weeks to 31 0\/7 weeks and birth weight range of 545 to 910 g with previously failed attempts at iNO weaning. The most common starting dose for sildenafil was 0.125 mg\/kg intravenously every 8 hours or 0.25 mg\/kg enterally every 8 hours. Four infants were able to discontinue iNO within 48 hours of sildenafil initiation, 1 patient discontinued iNO within 5 days, and 1 patient within 10 days of sildenafil initiation. One patient experienced weaning failure from iNO despite initiation of sildenafil. No adverse events, such as hypotension or deaths, were reported in any of the 7 infants.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Sildenafil facilitated weaning off iNO in most preterm neonates evaluated without adverse side effects.<\/jats:p>\n               <\/jats:sec>","DOI":"10.5863\/1551-6776-29.5.525","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T10:53:00Z","timestamp":1728903180000},"page":"525-529","source":"Crossref","is-referenced-by-count":0,"title":["Sildenafil as Bridge Therapy for Inhaled Nitric Oxide in Preterm Neonates"],"prefix":"10.5863","volume":"29","author":[{"given":"Harris","family":"Khawaja","sequence":"first","affiliation":[{"name":"Department of Pediatrics (HK, TAS, MS, GB), University of Chicago Medicine Comer Children\u2019s Hospital, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy A.","family":"Sanders","sequence":"additional","affiliation":[{"name":"Department of Pediatrics (HK, TAS, MS, GB), University of Chicago Medicine Comer Children\u2019s Hospital, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Schreiber","sequence":"additional","affiliation":[{"name":"Department of Pediatrics (HK, TAS, MS, GB), University of Chicago Medicine Comer Children\u2019s Hospital, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Bondi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (PS, DB), University of Chicago Medicine Comer Children\u2019s Hospital, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (PS, DB), University of Chicago Medicine Comer Children\u2019s Hospital, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian","family":"Brennan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics (HK, TAS, MS, GB), University of Chicago Medicine Comer Children\u2019s Hospital, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"issue":"3","key":"2024101410523642200_i2331-348X-29-5-525-b01","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/jama.2021.23580","article-title":"Mortality, in-hospital morbidity, care practices, and 2-year outcomes for extremely preterm infants in the US, 2013-2018","volume":"327","author":"Bell","year":"2022","journal-title":"JAMA"},{"issue":"12","key":"2024101410523642200_i2331-348X-29-5-525-b02","doi-asserted-by":"crossref","first-page":"e680","DOI":"10.1542\/neo.16-12-e680","article-title":"Persistent pulmonary hypertension of the newborn","volume":"16","author":"Lakshminrusimha","year":"2015","journal-title":"Neoreviews"},{"issue":"4","key":"2024101410523642200_i2331-348X-29-5-525-b03","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1203\/00006450-199704000-00002","article-title":"Effects of inhaled nitric oxide on pulmonary edema and lung neutrophil accumulation in severe experimental hyaline membrane disease","volume":"41","author":"Kinsella","year":"1997","journal-title":"Pediatr Res"},{"issue":"3","key":"2024101410523642200_i2331-348X-29-5-525-b04","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1542\/peds.101.3.325","article-title":"Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study","volume":"101","author":"Davidson","year":"1998","journal-title":"Pediatrics"},{"issue":"3","key":"2024101410523642200_i2331-348X-29-5-525-b05","first-page":"H875","article-title":"Hemodynamic effects of exogenous nitric oxide in ovine transitional pulmonary circulation","volume":"263","author":"Kinsella","year":"1992","journal-title":"Am J Physiol"},{"issue":"9","key":"2024101410523642200_i2331-348X-29-5-525-b06","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1056\/NEJM199702273360902","article-title":"Inhaled nitric oxide and persistent pulmonary hypertension of the newborn: The Inhaled Nitric Oxide Study Group","volume":"336","author":"Roberts","year":"1997","journal-title":"N Engl J Med"},{"issue":"5","key":"2024101410523642200_i2331-348X-29-5-525-b07","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1542\/peds.100.5.e7","article-title":"Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn","volume":"100","author":"Wessel","year":"1997","journal-title":"Pediatrics"},{"issue":"21","key":"2024101410523642200_i2331-348X-29-5-525-b08","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1161\/CIR.0000000000000329","article-title":"Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society","volume":"132","author":"Abman","year":"2015","journal-title":"Circulation"},{"issue":"1","key":"2024101410523642200_i2331-348X-29-5-525-b09","first-page":"CD000509","article-title":"Inhaled nitric oxide for respiratory failure in preterm infants","volume":"1","author":"Barrington","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"2024101410523642200_i2331-348X-29-5-525-b10","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.healun.2019.06.022","article-title":"2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT","volume":"38","author":"Hansmann","year":"2019","journal-title":"J Heart Lung Transplant"},{"issue":"12","key":"2024101410523642200_i2331-348X-29-5-525-b11","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/jp.2010.37","article-title":"The changing pattern of inhaled nitric oxide use in the neonatal intensive care unit","volume":"30","author":"Clark","year":"2010","journal-title":"J Perinatol"},{"issue":"4","key":"2024101410523642200_i2331-348X-29-5-525-b12","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1542\/peds.2014-3290","article-title":"Off-label use of inhaled nitric oxide after release of NIH consensus statement","volume":"135","author":"Ellsworth","year":"2015","journal-title":"Pediatrics"},{"issue":"4","key":"2024101410523642200_i2331-348X-29-5-525-b13","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa060442","article-title":"Early inhaled nitric oxide therapy in premature newborns with respiratory failure","volume":"355","author":"Kinsella","year":"2006","journal-title":"N Engl J Med"},{"issue":"22","key":"2024101410523642200_i2331-348X-29-5-525-b14","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa031154","article-title":"Inhaled nitric oxide in premature infants with the respiratory distress syndrome","volume":"349","author":"Schreiber","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"2024101410523642200_i2331-348X-29-5-525-b15","doi-asserted-by":"crossref","first-page":"e945","DOI":"10.1542\/peds.2011-1809","article-title":"Hospital variation in nitric oxide use for premature infants","volume":"129","author":"Stenger","year":"2012","journal-title":"Pediatrics"},{"issue":"3","key":"2024101410523642200_i2331-348X-29-5-525-b16","first-page":"284","article-title":"Implementation of an inhaled nitric oxide weaning protocol and stewardship in a level 4 NICU to decrease inappropriate use","volume":"27","author":"Hussain","year":"2022","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"1","key":"2024101410523642200_i2331-348X-29-5-525-b17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00000542-199907000-00041","article-title":"Sildenafil ameliorates effects of inhaled nitric oxide withdrawal","volume":"91","author":"Atz","year":"1999","journal-title":"Anesthesiology"},{"issue":"5","key":"2024101410523642200_i2331-348X-29-5-525-b18","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1161\/01.RES.73.5.808","article-title":"Negative feedback regulation of endothelial cell function by nitric oxide","volume":"73","author":"Buga","year":"1993","journal-title":"Circ Res"},{"issue":"6","key":"2024101410523642200_i2331-348X-29-5-525-b19","first-page":"2):H2216","article-title":"Direct and reversible inhibition of endothelial nitric oxide synthase by nitric oxide","volume":"268","author":"Ravichandran","year":"1995","journal-title":"Am J Physiol"}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/29\/5\/525\/3441581\/i2331-348x-29-5-525.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/29\/5\/525\/3441581\/i2331-348x-29-5-525.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T18:41:46Z","timestamp":1738780906000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/29\/5\/article-p525.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":19,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,10,14]]},"published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-29.5.525","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"type":"electronic","value":"2331-348X"},{"type":"print","value":"1551-6776"}],"subject":[],"published":{"date-parts":[[2024,10,1]]}}}